Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments—Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
Details
The document's own metadata, straight from the source system.
- Title
- Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments—Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
- Posted
- May 22, 2026
- Comment period
- May 22, 2026 – Jun 18, 2026
- FR Doc
- 2026-10321
- Topics
Overview
What the public is saying — stance, who's commenting, and the issues they raise.
Stance breakdown
Who commented
Breakdown by commenter type.
Comments over time
Weekly arrivals, stacked by stance.
Support × commenter type
How each type splits across stance.
Issues raised
The docket's canonical issues. Select one to browse its comments.
Position map
Who stands where on each issue?
Every non-silent position is backed by an excerpt from the comment.
Issues shown
Choose up to five.
| Organization | Vaccine updates and accessibility |
|---|
1 organization-typed comment could not be identified.
Explorer
Every mirrored comment — filter by stance, campaign, or issue.
- May 27, 2026Comment from Vasculitis FoundationSupportAdvocacy
The Vasculitis Foundation is commenting to emphasize the importance of vaccines for protecting immunocompromised individuals, including those with vasculitis, who may be unable to receive vaccinations themselves. They urge the FDA to ensure that vaccines, including the mRNA influenza vaccine, are updated, effective, and made available to the public in a timely manner.
Read comment → - May 26, 2026Comment from AnonymousSupportIndividualRead comment →
- May 25, 2026Comment from AnonymousSupportIndividualRead comment →
- May 24, 2026Comment from Brooke OroszSupportIndividualRead comment →